BRCA1 and neoplasm: Although both somatic and gBRCA1/2 aberrations, resulting in high tumor TMB, have been approved by the FDA to function as a companion diagnostic tool for only BRCA1/2-mutated OCs [9], the antitumor activity of PARPi in BRCA wild-type tumors has been gaining attention, called “beyond BRCA” efficacy [90].